Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs.
about
Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectivesTherapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer.Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter studySuppression of hepatic tumor growth and metastasis by metronomic therapy in a rat model of hepatocellular carcinomaMetronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer.Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.Controlling escape from angiogenesis inhibitors.Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity.Metronomic oral paclitaxel shows anti-tumor effects in an orthotopic mouse model of ovarian cancer.New anti-angiogenic strategies in pediatric solid malignancies: agents and biomarkers of a near future.Eradication of breast cancer cells in patients with distant metastasis: the finishing touches?Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer.The use of low-dose metronomic chemotherapy in dogs-insight into a modern cancer field.First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study.Dental pulp stem cells used to deliver the anticancer drug paclitaxel.Penetration and Silencing Activity of VEGF Dicer Substrate siRNA Vectorized by Chitosan Nanoparticles in Monolayer Culture and a Solid Tumor ModelIn Vitrofor Potential Application in Tumor Therapy
P2860
Q26751280-0BC71FA8-2738-4FFC-93F3-E68DE9F30CEFQ33884698-D26E4700-C6BD-4783-A311-172894898720Q34993605-29879D90-F637-45D5-A91F-DEDEFA03C4AAQ35014219-51A924DB-43E5-4D26-9551-C05AB867D9DBQ35247727-9E19D470-4D29-460D-82DA-0FFF768F16D7Q36618871-2D6A1B57-E5A2-4B6C-8499-711E68C008E5Q37672654-27CC0688-5C00-4792-99E1-B8D20341C7F9Q37702718-CB61ECDD-4573-4218-86A9-848471DB4EA1Q37717741-FEC73961-AF59-4A56-8DE1-7D968C9E8F76Q37752435-E35E18BF-FD9D-4220-AE3D-89939EE6D760Q37869838-B942670D-52BD-421F-A453-5B203DDDA7CBQ38969949-CD9C1F67-3E96-4631-9706-17249E94F185Q39186863-2EDC4C18-88B2-4D1D-8F1B-7D0CFC4F061CQ48686558-908F965F-37FC-43E5-BA14-1790D6FF145BQ52591382-93B7F25D-CF05-488A-B80E-70A60169F476Q59128522-A28E6059-D48C-42DF-BDA8-4C5723AEF121
P2860
Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Improving conventional or low ...... targeted antiangiogenic drugs.
@en
Improving conventional or low ...... targeted antiangiogenic drugs.
@nl
type
label
Improving conventional or low ...... targeted antiangiogenic drugs.
@en
Improving conventional or low ...... targeted antiangiogenic drugs.
@nl
prefLabel
Improving conventional or low ...... targeted antiangiogenic drugs.
@en
Improving conventional or low ...... targeted antiangiogenic drugs.
@nl
P2860
P1476
Improving conventional or low ...... targeted antiangiogenic drugs.
@en
P2093
Robert S Kerbel
P2860
P304
P356
10.4143/CRT.2007.39.4.150
P577
2007-12-31T00:00:00Z